IP Library Assignment 060921/0078
Patent Assignment
Reel/Frame 060921/0078

Change of Name

Recorded: 2022-07-26 Pages: 4
Assignor
CEPHALON, INC.
Executed: 2022-06-30
Assignee
CEPHALON LLC
145 BRANDYWINE PARKWAY, WEST CHESTER, PENNSYLVANIA, 19380
Covered Properties (24)
Anti-IL-5 Antibodies
Application: 17/385,532 →
Publication: US 2021/0355205
Bendamustine Pharmaceutical Compositions
Application: 16/695,624 →
Publication: US 2020/0237726
Pharmaceutical Prodrugs and Methods of Their Preparation and Use
Application: 17/384,350 →
Publication: US 2021/0361777
Anti-CXCR2 Antibodies and Uses Thereof
Application: 17/718,622 →
Publication: US 2022/0348671
Nanoparticulate and Macroparticulate Formulations
Application: 15/425,421 →
Publication: US 2017/0143640
Anti-IL-5 Antibodies
Application: 15/848,090 →
Publication: US 2018/0186873
Treatment Strategy for Non-Responders to 100MG Subcutaneous Mepolizumab
Application: 16/112,016 →
Publication: US 2019/0062421
Pharmaceutical Prodrugs and Methods of Their Preparation and Use
Application: 16/316,451 →
Publication: US 2019/0240348
Novel Pharmaceutical Formulations of Modafinil
Patent: 7,229,644 →
Application: 10/243,557 →
Publication: US 2003/0220403
Preparations of a Sulfinyl Acetamide
Patent: 6,875,893 →
Application: 10/443,327 →
Publication: US 2004/0002547
Bendamustine Pharmaceutical Compositions
Patent: 8,436,190 →
Application: 11/330,868 →
Publication: US 2006/0159713
Novel Solid Forms of Bendamustine Hydrochloride
Patent: 8,445,524 →
Application: 13/301,979 →
Publication: US 2012/0071532
Liquid Formulations of Bendamustine
Patent: 8,344,006 →
Application: 13/362,430 →
Publication: US 2012/0129904
Novel Solid Forms of Bendamustine Hydrochloride
Patent: 8,669,279 →
Application: 13/874,575 →
Publication: US 2013/0245086
Bendamustine Pharmaceutical Compositions
Patent: 8,461,350 →
Application: 13/654,898 →
Publication: US 2013/0041003
Bendamustine Pharmaceutical Compositions
Patent: 8,609,863 →
Application: 13/719,379 →
Publication: US 2013/0123316
Bendamustine Pharmaceutical Compositions
Patent: 8,895,756 →
Application: 13/719,409 →
Publication: US 2013/0131131
Bendamustine Pharmaceutical Compositions
Patent: 8,791,270 →
Application: 13/969,724 →
Publication: US 2013/0338205
Novel Solid Forms Of Bendamustine Hydrochloride
Patent: 8,883,836 →
Application: 14/200,738 →
Publication: US 2014/0187598
Nanoparticulate and Macroparticulate Formulations
Patent: 9,598,377 →
Application: 14/772,540 →
Publication: US 2016/0002173
Novel Solid Forms Of Bendamustine Hydrochloride
Patent: 9,533,955 →
Application: 15/045,523 →
Publication: US 2016/0159748
Novel Solid Forms of Bendamustine Hydrochloride
Application: 15/359,777 →
Publication: US 2017/0071913
Novel Solid Forms of Bendamustine Hydrochloride
Application: 16/037,560 →
Publication: US 2019/0015390
Anti-CXCR2 Antibodies and Uses Thereof
Application: 16/527,354 →
Publication: US 2020/0040089
Related Assignments (7)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Nov 26, 2002
From: CORVARI, VINCENT; GRANDOLFI, GEORGE; PARIKH, ALPA
To: CEPHALON, INC.
Reel/Frame 013267/0123 →
Assignment of Assignor's Interest Sep 2, 2003
From: LARGEAU, DENIS; ODDON, GILLES
To: CEPHALON, INC.
Reel/Frame 013935/0838 →
Assignment of Assignor's Interest Mar 14, 2006
From: BRITTAIN, JASON EDWARD; FRANKLIN, JOE CRAIG
To: CEPHALON, INC.
Reel/Frame 017302/0847 →
Assignment of Assignor's Interest Aug 23, 2012
From: JANSCH, HANS-JOACHIM
To: CEPHALON, INC.
Reel/Frame 028837/0632 →
Assignment of Assignor's Interest Jan 9, 2019
From: DRAGER, ANTHONY S.; WATTAMWAR, PARITOSH
To: CEPHALON, INC.
Reel/Frame 047941/0826 →
Assignment of Assignor's Interest Mar 10, 2020
From: NAIR, PARAMESWARAN; MUKHERJEE, MANALI
To: MCMASTER UNIVERSITY
Reel/Frame 052062/0409 →
Assignment of Assignor's Interest Mar 10, 2020
From: MCMASTER UNIVERSITY
To: CEPHALON, INC.
Reel/Frame 052062/0556 →